ENTREPRENEURIAL INVESTMENT PARTNERSHIP

„If somebody were to offer us another [1&1 stock] package, I'd take it as well. I'm still optimistic.“

Ralph Dommermuth, CEO of United Internet

April 20, 2026

Dear partners and supporters,

This is the Q1 2026 update of the Entrepreneurial Investment Partnership SICAV-RAIF (EIP). As of the reporting date of March 31, 2026, the capital under management amounts to EUR 44.5 million at a net asset value of EUR 10,859.55 per founding partner share, reflecting a 4.0% decrease compared to the beginning of the year. The Iran war has a measurable impact on the volatility of the partnership as today's price implies a +4.8% performance vs. the start of the year (+9.2% in April).

The two largest detractors during the quarter were Ocado (EUR -0.9 million/-1.9%) and Zalando (EUR -0.8m/-1.7%), while Rocket Internet (+1.4 million/+3.0%) and ROVI (+0.9 million/+2.0%) contributed positively.

During the quarter, EIP sold shares in ROVI (EUR 1.6 million), DocMorris (EUR 0.9 million) and 1&1 (EUR 0.2 million) due to more attractive reinvestment opportunities. EUR 1.6 million was reinvested in Redcare Pharmacy (better known as the DocMorris competitor Shop Apotheke), Zalando (EUR 1.0 million), BioNTech (EUR 0.5 million), Rocket Internet (EUR 0.4 million), and Ocado (EUR 0.3 million).

Company	as % NAV
United Internet AG Namens-Aktien o.N.	29.3%
Rocket Internet SE Inhaber-Aktien o.N.	13.8%
1&1 AG Inhaber-Aktien o.N.	11.4%
Zalando SE Inhaber-Aktien o.N.	9.1%
BioNTech SE Nam.-Akt.(sp.ADRs)1/o.N.	7.0%
Ocado Group PLC Registered Shares LS -,02	6.6%
Laboratorios Farmaceut.Rovi SA Acciones Port. EO -,06	6.3%
Haier Smart Home Co. Ltd. Registered Shares D YC 1	5.2%
DocMorris AG Namens-Aktien SF 0,01	4.4%
Modern Times Group MTG AB Namn-Aktier B o.N.	3.4%
Redcare Pharmacy N.V. Aandelen aan toonder EO -,02	2.2%
Articore Group Ltd. Registered Shares o.N.	0.9%
Cash in EUR	0.4%

At the reporting date, EIP owned squeeze-out improvement rights in Aareal Bank AG (EUR 5.3 million worth of shares squeezed out), Software AG (EUR 4.1 million), and About You Holding SE (EUR 2.0 million) that are valued at zero according to the standard accounting practice as the outcome is uncertain and dependent on the court proceedings. You will find prior updates via the partner login: `link` and the password "p4rtn3r!".

Let's briefly revisit the pillars of the EIP investment philosophy and portfolio management approach for new readers:

- Industries with a long runway of growth, and a high and predictable return on capital.
- Management teams that have skin-in-the-game, strong capital allocation track records, and the ability to lead people to do their best work.
- The stock price should trade significantly below what a private equity investor would pay for the whole company.

For an overview how the companies fit this philosophy, please access the company overview (`link`). EIP reviews thousands of listed companies every year to find the best meeting these criteria. Not all portfolio companies will score equally high in each dimension. After investing, companies remain in the portfolio as long as the companies develop as expected and remain undervalued. As valuations fluctuate, the share of each investment is adjusted accordingly.

ROVI - business and share price firing on all cylinders

The share price of ROVI (Spanish pharma and syringe filling company introduced in the Q2 2025 update (`link`) fluctuated materially upwards during the last year. A few months after EIP's investment, it announced the acquisition of a US-based syringe filling facility and a syringe filling deal with Roche that could secure a significant share of the 2030 guidance. Furthermore, the company is vertically integrating the supply of key ingredients for its heparins and ramping up the joint venture production facility in Spain. In addition, its own schizophrenia drug Okedi, with the advantage of monthly instead of daily dosing, grew revenues by 100% in 2025 to c. EUR 60 million and should have the potential triple sales. The company is continuing research to bring a drug for breast cancer hormone treatment to the market that is based on the technology of Okedi and would enable monthly dosing instead of daily dosing. ROVI's share price increased by c. 70% compared to EIP's acquisition of shares only a year ago and is now trading at c. 18x enterprise value / EBITDA for 2026 estimates. As the company and its outlook have not improved by 70%, selling shares to invest in more attractive opportunities made sense despite the continuing bright outlook.

United Internet / 1&1 - investing to double EBITDA to EUR 1 billion in 2028 at 1&1

United Internet is the holding of 1&1, IONOS and email assets GMX/Web.de and was introduced in the November 2021 update (`link`). 1&1's build out of the fourth mobile network in Germany based on open-ran technology is progressing well. The company has passed its low point in EBITDA in 2025 of EUR 540 million impacted by one-off migration costs of customers to its own network. As such, 2026 EBITDA is forecasted by the management to rise to c. EUR 800 million with annual increases of EUR 100 million in 2027 and 2028. The company is achieving this by building more antenna sites and edge data centers to broaden its network coverage. This decreases roaming payments to Vodafone, so the return on CAPEX is very predictable. CAPEX is forecasted to be at c. EUR 500 million p.a. over the same three year period, of which c. EUR 200 million are attributable to fiber infrastructure investment. The current 1&1 valuation implies an enterprise value / EBITDA multiple of c. 7x on the 2028 EBITDA management guidance. Open ran technology has lower maintenance CAPEX needs than traditional networks, which should result in an improved cash conversion.

The assets of 1&1 include 16 million customers contracts, the second largest fiber backbone at c. 70.000 km of fiber network in Germany after Deutsche Telekom, and a running mobile network with the potential to internalize the roaming costs paid to Vodafone until the roaming contract runs out in 2042. As Mr. Dommermuth announced to be interested in increasing United Internet's 87% stake in 1&1, it could well lead to EIP's fourth squeeze-out case. The implied return on CAPEX may appear modest at first glance (EUR 100 million higher EBITDA on EUR 500 million CAPEX) and one reason is that fiber network CAPEX is already good at 10-15% returns due to their long useful life. The other reason: If you want to buy more shares, issuing an optimistic guidance is contrary to your incentives.

IONOS (listed domain and hosting business, 64% stake) continues to perform well and has increased operating income by c. 60% (27% EBIT margin in 2025) since EIP's first investment in United Internet 2021. Due to the AI scare, its valuation has decreased to c. 8x enterprise value / EBITDA on a 2026 estimate at EUR 530 million EBITDA in the last weeks. At c. 5% of EBITDA as maintenance CAPEX, the market does not see much potential for the future of the company. It is not clear to me how AI could replace the management of c. 30 data centers of IONOS [1].

Instead of being a risk, refining available AI products for IONOS' 6 million non-technical SME customers is a big opportunity. As an example, IONOS has introduced an AI phone receptionist in December that starts at EUR 19 per month - more than the current average total monthly spend of the average IONOS customer. It takes calls, provides callers with information about your company, schedules appointments, and writes email summaries whom to call back. Surely, the voice model provider will earn a good chunk of the revenue, while IONOS can freely switch model providers after contracts run out. I believe at the current competitive intensity in the AI field, value-added AI distribution is a good business to be in and the company has plans for more than a dozen AI agents it plans to introduce to its customers.

On another front, IONOS has announced to introduce an open-source alternative to Microsoft Office in the wake of EU software sovereignty efforts. The suite will be available this year, it will be GDPR compliant and enable real-time collaborative editing. By coincidence, Germany's new digital minister Mr. Wildberger announced to search for alternatives to Microsoft Office for the Bund's employees. As open-source software needs to be hosted somewhere, IONOS could be soon in the pitch to do it for millions of federal employees of Germany.

DocMorris / Redcare Pharmacy - acquisition of shares in Redcare

The share price of Redcare (Shop Apotheke) fell c. 60% in the last year. A few weeks ago, c. 16% of its shares were being sold short. As the DocMorris valuation decreased less and they are largely addressing the same market, it made a partial shift of the DocMorris investment into Redcare sensible.

As you can recap from the investment introduction to DocMorris in the Q1 2025 update (`link`), Redcare is the leader in the German e-commerce pharmacy market being roughly twice as large

[1] On a less serious note, even the AI does not believe it can replace IONOS as you can check at: `https://deathbyclawd.com`. Mind the imaginary quote of Anthropic's Claude at the bottom.

as DocMorris. It has, due to scale, reached EBITDA profitability in the pharmacy e-commerce segment. Redcare's management plans this year as the last year of negative cash flow due to revenue growth, marketing cost reduction and this year's one-time growth investment in automation technology and capacity upgrades in their Netherlands logistics center. Despite its smaller size and at best similar fixed cost structure, DocMorris management is planning to reach cash flow breakeven in 2027 as well, due to the mid double digit growth rates and profitability of its crown jewel asset Teleclinic (doctor appointment video platform in Germany). Teleclinic is growing revenues at 120% in 2025 to c. EUR 25 million c. 50% operating margin and should continue to grow its top line mid double digits. More by dumb luck than careful planning, Teleclinic is the only successful acquisition of a flawed m&a and marketing strategy of the last several years at DocMorris. Redcare is still guided by its founder Michael Köhler (8% ownership), who focused largely on executing on organic growth and overtook DocMorris by revenue in 2022. Until now, this has commanded a higher valuation Redcare despite owning nothing comparable to Teleclinic.

The shortcomings at DocMorris are being addressed. In the discussions I had with its larger shareholders the need for change was omnipresent and the pressure on the board and management increased materially in the last months. The largest shareholder at 15%, Pelion S.A., (a polish pharma wholesaler and pharmacy chain operator in the Netherlands) decided to go his own way by trying a hostile takeover of the board members at the upcoming AGM next month. Trying to preempt the obvious, DocMorris is itself proposing 3 new board members that seem better qualified and safer than Pelion's candidates. While nobody would hand half of the board to a rather unknown 15% investor with unclear ambitions, their pitch for change, increased urgency and cost efficiency is resonating and will help to improve the governance beyond the upcoming AGM. Also the management is improving, as Andrea Skersies, former Chief Marketing Officer at Zooplus, joined DocMorris as head of marketing in Q4 2025. There should be considerable improvements in marketing efficiency observable in the next quarters.

In the e-commerce segment both companies are addressing the EUR 60 billion prescription drug market in Germany that is now conveniently addressable by e-commerce pharmacies via electronic prescription. Due to a favorable court ruling last year, pharmacies can offer cash-back options to customers for redeeming prescriptions with them, what strengthens the e-commerce proposition further. As such, the underlying growth of the e-prescription is in the mid double digits and should continue to grow for the next decade. In addition, DocMorris has Teleclinic as a profitable "rule of 40" company in itself that is financing the investment in its e-commerce segment. Consolidation of the two could offer a mid double digit million synergy potential as the Zalando and About You combination has demonstrated in a related industry. I believe the best years are yet to come.

Zalando - faster than expected synergy realization and EUR 300 million buyback

Zalando is integrating its acquisition of About You and has announced to reach the projected synergies of c. EUR 100 million (c. 25% of 2025 EBIT) earlier than planned. The ad business continues to grow at c. 40% p.a. and will drive profitability further. Zalando's software entity Scayle has announced jeans company Levis as its first major US customer that is replatforming from Saleforce's legacy software Commerce Cloud. Levis will be introducing Scayle for its global e-commerce operations that account for c. USD 600 million in revenue. As Scayle's average take-rate is around 0.7% of merchandise value sold, it could well be a USD 3 million per year revenue deal (90% gross margin). Management announced in March that it believes the market undervalues the company and introduced a EUR 300 million buyback program (c.

5% of outstanding shares). I don't feel bad about the share price remaining low as it makes the buyback more efficient and enabled EIP to increase the investment further.

This quarter, the lawyers of Dreier&Riedel filed the About You squeeze out case in the name of EIP and other investment funds. Several points speak for grave errors of the valuation appraisal, and I believe there is a decent chance EIP could receive a compensation in a few years that would be payable at interest of 5% plus base rate.

BioNTech - founders ”leaving” as a good and logical step

It was broadly discussed in the media that BioNTech founders have decided to step down from their management roles to found a new company. Few media headlines suggested it to be a reasonable decision and natural step that could be beneficial for all stakeholders, what would be boring and likely attract little clicks and ad revenue. As introduced in the May 2022 update (`link`), BioNTech was Uğur Şahin and Özlem Türeci's second company, founded in 2008. They started it, while they were still engaged at their prior company Ganymed that they had founded in 2001. Back then, they had hired a CEO to run the day-to-day operations to focus on their passion of doing pioneering research. Ganymed was sold in 2016 and commercialized the first available drug treating stomach cancer in 2024 after 23 years of research.

At the end of this year, BioNTech is expected to be in 15 phase 3 trials, and with some luck could receive the first commercial license at the end of this year - 18 years after founding the company. It employs now c. 8.000 people in a listed company and needs to manage the post-merger integration of CureVac of c. 1.000 people. Naturally, the speed boat becomes a tanker that needs a different management skillset, focus and time dedication that is at odds with the passion and talent of the two founders.

While every company would be more than happy to retain 100% of their talent, they are able to raise funding in the venture capital market at terms that will make most founders envious. As BioNTech owns the patents and technology they need to continue working in their field of m-rna technology, there should be some leverage in the negotiations from the BioNTech side and the board with the Strüngmann brothers as 40% shareholders should protect all shareholders' interest. After all, the founders also still own 15% of BioNTech - why would they leave, if they felt their skills were still needed to protect what they had build for more than a decade? As with Ganymed, I don't believe there will be any impact of the founders ”leaving” on the success of the current late stage pipeline. As such, EIP bought more shares as the prices were down 20% on the day of the announcement.

While it remains to be seen how the Iran war, ETF concentration, AI CAPEX, private debt markets, record budget deficits, demographics, etc., will continue to impact markets, I remain optimistic for the outlook of EIP's companies and treat volatility as opportunity.

If you have any questions, I'd be happy to discuss them.

Thank you for your continued trust and support,

Tim Jeck

Disclaimer

This document is a customer / marketing information ("CI") within the meaning of the German Securities Trading Act, the "CI" is addressed to natural persons and legal entities with their habitual residence or registered office in Germany and is used exclusively for informational purposes and therefore considered a "non-mandatory investor information". This "CI" cannot replace an individual investment- and investor-friendly advice and does not justify a contract or any other obligation or represent any kind of contractual offer. Furthermore, the contents do not constitute investment advice, an individual investment recommendation, an invitation to subscribe for securities or a declaration of intent or a request to conclude a contract for a transaction in financial instruments. Also, it was not written with the intention of providing legal or tax advice. The tax treatment of future transactions as well as the fund performance depends on the personal circumstances of the respective customer and may be subject to future changes. The individual circumstances of the recipient (including the economic and financial situation) were not taken into account in the preparation of the "CI". An investment in mentioned financial instruments / investment strategy / financial service involves certain product specific risks - e.g., Market or industry risks and risk in currency, default, liquidity, interest rate and credit - and is not suitable for all investors. Therefore, potential prospects should make an investment decision only after a detailed investment advisory session by a registered investment advisor and after consulting all available sources of information. For further information and as sole basis for a potential fund purchase, please refer to the "Key Investor Information" and the prospectus (available in German language) from Hauck & Aufhäuser Fund Services S.A. The management company (AIFM) may decide to suspend the arrangements it has made for the marketing and distribution of the funds in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU. Past performance is not a reliable indicator of future performance. Recommendations and forecasts are non-binding value judgments about future events and may therefore prove to be inaccurate with respect to the future performance development of a product. Investment funds are subject to price fluctuations, which can lead to losses of the investment – up to the total loss. The listed information refers exclusively to the time of the creation of this "CI", a guarantee for timeliness and continued correctness cannot be given. The above content reflects only the opinions of the author, a change of opinion is possible at any time, without it being published. The present "CI" is protected by copyright, any duplication and commercial use are not permitted. For the date of publication see the first page of the document. EIP Entrepreneurial Investment GmbH, Leopoldstraße 20, 80802 München acts as a tied agent (section 3 (2) German Wertpapierinstitutsgesetz (WpIG)) on behalf of, in the name of, for account and under the liability of the responsible legal entity NFS Netfonds Financial Service GmbH (NFS). NFS has a corresponding license (section 15 WpIG) from the German Federal Financial Supervisory Authority (BaFin) for the provision of investment advice in accordance with section 2 (2) no. 4 WpIG and investment brokerage according to section 2 (2) no. 3 WpIG.